Research programme: bacterial and viral vaccines - Berna Biotech/HesperionAlternative Names: Vaccines research programme - Berna Biotech/Hesperion
Latest Information Update: 04 Jun 2007
At a glance
- Originator Berna Biotech
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bacterial infections; Viral infections
Most Recent Events
- 25 Mar 2004 Hesperion has been acquired by Cerep
- 05 Feb 2003 Preclinical trials in Viral infections in Switzerland (unspecified route)
- 05 Feb 2003 Preclinical trials in Bacterial infections in Switzerland (unspecified route)